ArticlePLoS neglected tropical diseases2018
Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus.
Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.Fundamental & clinical pharmacology · 2021Pooled it
- Trial
- Efficacy of high doses of ivermectin-clorsulon in cattle on Glossina palpalis gambiensis survival and fecundity: implications for human and animal trypanosomoses control.Parasites & vectors · 2026Article
- Toxicity of ivermectin on multiple insecticide-resistant populations of Anopheles gambiae sensu lato, Aedes aegypti, and Culex mosquitoes.Parasites & vectors · 2026Article
- Article
- Dengue virus: pathogenesis and potential for small molecule inhibitors.Bioscience reports · 2024Review
- Exploring the Targets of Dengue Virus and Designs of Potential Inhibitors.Combinatorial chemistry & high throughput screening · 2024Article
- Machine learning and molecular docking prediction of potential inhibitors against dengue virus.Frontiers in chemistry · 2024Article
- Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model.The Journal of antibiotics · 2023Article
- Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors.International journal of molecular sciences · 2023Article
- Recent updates on the biological efficacy of approved drugs and potent synthetic compounds against SARS-CoV-2.RSC advances · 2023Review
- Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations.BMC pharmacology & toxicology · 2022Article
- Repurposing the drug, ivermectin, in COVID-19: toxicological points of view.European journal of medical research · 2022Review
- Expression of Concern: Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus.PLoS neglected tropical diseases · 2022Article
- Evaluation of an ivermectin-based attractive targeted sugar bait (ATSB) againstWellcome open research · 2022Article
- A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Emerging therapeutics in the management of COVID-19.World journal of virology · 2021Review
- COVID-19 and Possible Pharmacological Preventive Options.Journal of clinical medicine research · 2020Review
- Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments.International immunopharmacology · 2020Review
- Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects.Pharmaceuticals (Basel, Switzerland) · 2020Review
Corrections and comments
- Expression of concern · 2022-01-11Concerns/Issues about Data · Investigation by Journal/Publisher · Investigation by Third Party ·
- Expression of concern
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDengue fever is the most rapidly spreading mosquito-borne viral disease over the past 50 years, with a 30-fold increase in global incidence. Dengue vector control is a key component for the dengue control strategy, since no absolutely effective vaccine or drug is available yet. However, the rapid rise and spread of mosquito insecticide resistance have become major threats to the efficiency of insecticide-based vector control activities. Thus, innovative vector control tools are badly needed. This study aims to confirm the antivirus effectiveness of ivermectin on dengue virus type 2 (DENV-2) in Aedes albopictus (Skuse, 1894), then to explore its potential use in the combating to the dengue epidemics.
methodsAedes albopictus were first infected with DENV-2 in human whole blood, and at the fourth day after infectious blood feeding, they were divided into eight groups. Seven of them were held for six days with access to 0, 2, 4, 8, 16, 32 and 64 ng/ml ivermectin, respectively, and the last one was set as a historical control group, which was stored at -80°C until being detected at the same time with the other groups. Each mosquito was detected using real-time fluorescent RT-PCR kit. DENV-2 RNA concentration (copies/ml) and infection rate in each group were compared.
resultsBoth of quantitatively and qualitatively inhibiting effects of ivermectin have been detected in this study. Generally, DENV-2 replicated well in Aedes albopictus without ivermectin intervention, whose virus loads exhibited significantly higher when the mosquitoes were holding from 4 days to 10 days after infectious blood feeding. In contrast, with the treatment of ivermectin, the infection rate was reduced by as much as 49.63%. The regression equation between infection rates (Y2) and ivermectin concentration log2 values (X2) was obtained as Y2 = 91.41-7.21*X2 with R2 = 0.89.
conclusionIvermectin can directly or indirectly inhibit DENV-2 multiplication in Aedes albopictus. Moreover, the actual concentration for application in zooprophylaxis needs to be confirmed in the further field trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.